• Protocols

• EA1211

  OPEN TO ACCRUAL

  Interim FDG-PET/CT for Predicting Response of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT trl
  
  

• UW20100

  OPEN TO ACCRUAL

  Ph II Pre-Op Neratinib + Endocrine Therapy w/ Trastuzumab in Triple-Positive Breast Cancers